Contract Testing News Today

kevin oconnell put on a one page memo today to white house press secretary saying the president is doing okay. did catch people off guard but not only members of the media but also clearly the president himself. the white house today it was planning on the president going to wilmington, delaware tomorrow for a few days and just announce the trip a couple of hours ago a tuesday trip to hemlock, michigan to talk about the economy put both of those have been canceled. a wintry part of the...

* AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer. PHILADELPHIA, PA. - WuXi Advanced Therapies , a wholly owned subsidiary...

Government officials want scrutiny of labor practices as the fast-fashion behemoth's potential IPO looms on the horizon.

– Initial clinical data from CABA-201 treated patients in Phase 1/2 trials for lupus and/or myositis expected in the first half of 2024, with the ...

/PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and...

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients.

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients.

- Agreement expansion facilitates preparation for commercial readiness for CABA-201, enabling treatment of patients in multiple planned clinical trials with separate parallel cohorts...

– Agreement expansion facilitates preparation for commercial readiness for CABA-201, enabling treatment of patients in multiple planned clinical trials with separate parallel cohorts – –...

Revenue of RMB9,908 Million in the Second Quarter, Up 6.7% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 39.5% Revenue of RMB18,871 Million in the...